CervoMed is expected to report a consensus EPS of -$0.61 on grant-related revenue of $0.05 million, with the current stock price of $1.53 sitting significantly below the $15.50 average analyst price target.
Investors are primarily focused on management's strategy for a pivotal Phase 3 trial following the mixed RewinD-LB Phase 2b results released in late October. While the trial missed its primary endpoint in the general population, analysts are highlighting the robust efficacy signals observed in the "pure" DLB patient subgroup as a path forward. Additionally, stakeholders are watching for updates on potential strategic partnerships and the upcoming Phase 2a biomarker data for nfvPPA expected later this month.